Carglumic Acid Market Analysis | 2021-2026

"The Carglumic Acid Market is estimated to grow from USD 122.3 million in 2020 to USD 188.8 million by 2026 at a healthy CAGR of 7.7% during the forecast period".

Figure: Carglumic Acid Market Size, 2020-2026 (USD Million)

Wish to get a free sample? Register Here

Market Dynamics

Introduction

Carglumic acid is stated as an orphan drug that's mainly used to treat hyperammonemia, also called NAGS Syndrome. This rare genetic defect happens primarily thanks to a lack of an enzyme called N-acetyl glutamate synthase (NAGS) within the liver. This results in increased levels of ammonia within the blood. Several neurological disorders like hepatic encephalopathy, congenital deficiencies of urea cycle enzymes, and Reye’s syndrome, among other metabolic disorders, arise with the high levels of ammonia demanding the requirement for carglumic acid.

Market Drivers 

Carglumic acid has significantly gained popularity as it is used to treat urea cycle disorders, thus, augmenting the market growth. The deficiency of two transporters or any one of the hepatic enzymes that are engaged in the detoxification of ammonia causes urea cycle disorders. This further results in severe brain injury, which can only be prevented by reducing the build-up of ammonia, the most toxic metabolite. Carglumic acid has thus been increasingly used for the treatment of multiple disorders such as treating patients with hyperammonemia, preventing ammonia intoxication, preventing brain damage, accelerating cancer cell suppression & promoting apoptosis.

Covid-19 Impact Analysis

The outbreak of COVID-19 significantly impacted the carglumic acid industry as the pandemic adversely affected international trade activities, supply chains, and manufacturing activities across the globe. Moreover, the production of carglumic acid reduced amidst the COVID-19 pandemic as the industry players had to temporarily shut down production facilities or operate the facilities below the optimal production capacities to prevent the spread of coronavirus infection.

Segment Analysis

Distribution Channel Trends

"Hospital pharmacies segment held a substantial market share of more than 50% in 2020"

Based on distribution channels, the carglumic acid market has been divided into hospital pharmacies, retail pharmacies, and e-commerce channels. The hospital pharmacies segment held a substantial market share in 2020. This is mainly attributed to well-established hospital infrastructure, easy availability of medicines, up-to-date stocking of medicines, offers patients ease, preference for the purchase of drugs, and easy reliability of pharmacy stores.

Regional Trends

"North American Carglumic Acid market accounted for the largest share of almost 40% in 2020"

By region, the North American Carglumic Acid market accounted for the largest share in 2020 and is expected to grow at a significant CAGR during the review period. The carglumic acid market growth can be ascribed to strong healthcare expenditure, the presence of highly qualified healthcare professionals, and a significant rise in ammonia levels in patients leading to extensive muscle contractions.

The Asia-Pacific Carglumic Acid market is expected to grow at the highest CAGR during the review on account of the growth of the major end-use industries. China is the key contributor owing to the presence of a large population which adds to the prevalence of rare diseases. Moreover, improving medical infrastructure in developing countries as well as favorable government support further bolsters the regional market growth in the coming years.

Key Players

The following are the key players in the Carglumic Acid Market (arranged alphabetically)

• Apothecon Pharmaceuticals Pvt Ltd (India)
• Biophore India Pharmaceuticals Pvt Ltd (India)
• Civentichem LLC (US)
• Dipharma S A (Switzerland)
• Manus Aktteva Biopharma LLP (India)
• NURAY CHEMICALS (India)
• NOVITIUM PHARMA LLC (US)
• Recordati Rare Diseases Inc (US
• Suven Life Sciences Limited (India

Report Features

This report provides market intelligence most comprehensively. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision-making for the existing market players as well as those willing to enter the market.

What Deliverables Will You Get in this Report?

Research Methodology

This report offers high-quality insights and is the outcome of a detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders, and validation and triangulation with Stratview Research’s internal database and statistical tools.

More than 1,000 authenticated secondary sources, such as company annual reports, fact books, press releases, journals, investor presentations, white papers, patents, and articles have been leveraged to gather the data.

We conducted more than 15 detailed primary interviews with the market players across the value chain in all four regions and with industry experts to obtain both qualitative and quantitative insights.

Customization Option

With this detailed report, Stratview Research offers one of the following free customization options to our respectable clients:

Company Profiling

• Detailed profiling of additional market players (up to three players)
• SWOT analysis of key players (up to three players)

Competitive Benchmarking

• Benchmarking of key players on the following parameters: Product portfolio, geographical reach, regional presence, and strategic alliances.

Custom Research:

Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to sales@stratviewresearch.com.